Mechanism of Action
Sulfinpyrazone is a classic example of uricosuric agents—a pharmacological group whose action aims to increase uric acid excretion from the body. It is important to understand the fundamental difference of this group: the drugs do not block uric acid synthesis itself (unlike synthesis inhibitors), but interfere exclusively with its renal excretion processes.
At the cellular level, the mechanism of Sulfinpyrazone involves direct competition with uric acid molecules for specific transport systems located in the renal tubules. The drug causes selective blockade of urate reabsorption. The primary site of action is the distal nephron. As a result of this pharmacological blockade, uric acid loses its ability to return to the systemic circulation, which logically leads to a significant increase in its excretion with urine.
Pharmacological Effects and Indications
The key pharmacological effect of Sulfinpyrazone is a sustained decrease in plasma uric acid levels.
In clinical practice, the drug is used for chronic treatment, meaning long-term prevention of attacks in conditions accompanied by hyperuricemia. By lowering plasma urate concentrations, the drug prevents their tissue deposition, thereby minimizing the risk of new acute attacks. Uricosuric agents are not used to treat an already developed acute attack; their main goal is systematic control of blood urate levels.
Side Effects
The use of Sulfinpyrazone requires careful patient monitoring due to the risk of serious adverse reactions affecting various organ systems:
- Hematotoxicity: the drug can suppress the hematopoietic system. This may manifest as agranulocytosis, leukopenia, thrombocytopenia, and anemia. Patients require regular complete blood count monitoring.
- Dyspeptic disorders: nausea and severe abdominal pain are frequently observed from the gastrointestinal tract.
- Risk of kidney stones: because the drug forces uric acid excretion, its concentration in the renal filtrate rises sharply. This creates a direct threat of urate crystallization directly in the urinary tract, followed by stone formation.
Administration Guidelines and Complication Prevention
The drug is available as 0.1 g tablets. Administered orally, the standard dosing regimen is 0.1 g 4 times daily. It is strictly recommended to take the drug with meals, which helps reduce the risk of the dyspeptic disorders described above.
To prevent the most severe complication—uric acid crystallization in the renal filtrate—Sulfinpyrazone therapy must be accompanied by two mandatory preventive measures:
- High fluid intake: necessary to mechanically increase urine volume and lower urate concentration in the renal tubules.
- Urine alkalinization: patients are additionally prescribed agents that shift urine pH to the alkaline side (e.g., potassium citrate). In an alkaline environment, uric acid solubility increases significantly, preventing crystal formation.